• Tony S Mok, Qing Zhou, Linda Leung, and Herbert H Loong.
• Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China. tony@clo.cuhk.edu.hk
• Expert Rev Anticancer Ther. 2010 Oct 1; 10 (10): 1601-11.

AbstractNon-small-cell lung cancer (NSCLC) is a heterogeneous illness associated with a high mortality rate. Personalized therapy may improve treatment outcomes by identification of a specific genotypic anomaly and target-specific therapy. The most significant development in recent years was the discovery of activated EGF receptor (EGFR) mutations at exons 19 and 21. Patients with EGFR mutations respond dramatically to EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib, resulting in longer progression-free survival. Multiple randomized studies, including the Iressa Pan-Asia Study and WJTOG3405, have confirmed the role of EGFR tyrosine kinase inhibitors as standard first-line therapy for patients with the EGFR mutation. In this article, we summarize the current nonpersonalized therapies and examine the available and investigational personalized therapies for patients with resectable early-stage, unresectable locally advanced, or metastatic disease.

24 keywords...

hide…